Abstract
Circadian rhythm disturbance is a common feature of psychiatric disorders. Light is the primary input to the circadian clock, with daytime light exposure strengthening rhythms and nighttime light exposure weakening rhythms. However, the independent effects of day and night light exposure on psychiatric outcomes have not been well characterized. In this study, we performed the largest to-date cross-sectional analysis of objectively measured day and night light exposure and examined their relationship with psychiatric disorders. UK Biobank cohort participants aged 37-73 years were recruited into the UK Biobank general cohort population. In a subset of participants (n=86,772; 43% male), light and physical activity patterns were monitored for ∼7 days. Using regression models adjusted for age, sex, ethnicity, photoperiod (day length), employment, and physical activity, we examined the independent associations of day and night-time light with psychiatric disorders and measures of symptom severity. We found that greater night light exposure was associated with greater odds of major depressive disorder (MDD), generalized anxiety disorder (GAD), bipolar disorder, post-traumatic stress disorder (PTSD), self-harm behavior and psychotic experiences. Conversely, greater daytime light exposure was associated with lower odds of MDD, PTSD, self-harm behavior and psychotic experiences. There was no significant association of day light exposure with GAD or bipolar disorder. Our findings demonstrate that low day light and bright night light exposure are associated with a wide range of psychiatric outcomes. Avoiding light at night and seeking light during the day may be a simple and effective, non-pharmacological means of broadly improving mental health.
Competing Interest Statement
AJKP and SWC have received research funding from Delos and Versalux, and they are co-founders and co-directors of Circadian Health Innovations PTY LTD. SWC has also received research funding from Beacon Lighting and has consulted for Dyson.
Funding Statement
Funded in part by the Australian Government Research Training Program and National Health and Medical Research Council (NHMRC; project number = GNT1183472).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used ONLY openly available human data originally located at the UK Biobank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.